Lunai Bioworks Inc.

LNAI

$2.30

-2.09%

2026-09-04 12:33:39 EDT-$0.05

Healthcare

Biotechnology

NASDAQ

Active Trading

Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments ...

Price Action of LNAI

$2.30

-2.09%-$0.05

High—

Low—

52W High-87.1%

Rel. vol—

Interval

Range2.5h

Volume—SMA5SMA10

—

Lunai Bioworks Inc. (NASDAQ: LNAI) is a biotechnology company headquartered in Los Angeles, California, that leverages artificial intelligence (AI) to advance medical treatments and strengthen biological defense systems. Formerly known as Renovaro Inc., the company rebranded to Lunai Bioworks in August 2025 to reflect its strategic pivot toward AI-powered drug ...Lunai Bioworks Inc. (NASDAQ: LNAI) is a biotechnology company headquartered in Los Angeles, California, that leverages artificial intelligence (AI) to advance medical treatments and strengthen biological defense systems. Formerly known as Renovaro Inc., the company rebranded to Lunai Bioworks in August 2025 to reflect its strategic pivot toward AI-powered drug discovery and biodefense. The company's core focus is on integrating AI, phenomics, and living biological systems to decode disease mechanisms and develop precise therapeutic interventions. A key project under development is its specialized 'Neurotoxicity Intelligence Technology,' which aims to address neurological conditions. Lunai Bioworks operates through subsidiaries such as BioSymetrics and BrainStorm Therapeutics, and has signed a Letter of Intent with Geneial to collaborate on AI-driven drug development. The company is led by CEO David Weinstein, who was appointed in October 2024. With a small team of 29 employees, Lunai Bioworks is in its early stages, with minimal revenue and significant research and development expenditures, as reflected in negative profit margins and cash flows. The company's financial metrics indicate heavy investment in R&D (R&D-to-revenue ratio of 7.948) and high SG&A costs (458.364% of revenue), typical for a pre-commercial biotech. Despite challenges, the company is focused on building its pipeline and leveraging AI for innovative therapies. Its stock trades on NASDAQ under the symbol LNAI, with a market cap of approximately $10.65 million as of the latest data. The company's future depends on successful development and commercialization of its AI-driven technologies and collaborations.ExpandCollapse

Founded

2025

Employees

CEO

David H. Weinstein

Full Name

Lunai Bioworks Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

892.52%

Market Cap

$0.01B

Current Ratio

0.19

WACC

6.77%

ROIC

1350.38%

Contact Information

https://www.lunaibioworks.com

305 918 1980

2080 Century Park East, Los Angeles, CA 90067

Key Metrics of LNAI

Snapshot

Latest / TTM · 5 periods

Market Cap

$10.43M

ROCE

104.4%

EV / EBITDA

-0.07x

+15.8% YoY

FCF Yield

-49.2%

-28.2% YoY

Cash Conversion Cycle

-47952.5d

Current Ratio

0.19

Quick take

TTM —

Current ratio below 1.0

Negative working capital

Financial Highlights of LNAI

Profitability trend

Latest / TTM · 5 periods

Gross Margin

-360.7%

Net Margin

-612568.1%

P/E Ratio

-0.04x

n/a

Debt / Equity

-0.15

n/a

Current Ratio

0.19

Dividend Yield

0.0%

Understanding

TTM —

Current ratio below 1.0

Interest coverage is weak

Calendar of LNAI

Recent history

May 15, 2026
Q3 FY2025 · Results reported
EPS $-0.80 · Revenue $20942.00
View filing
Feb 17, 2026
Q2 FY2025 · Results reported
EPS $-0.61 · Revenue $0.00
View filing
Nov 14, 2025
Q1 FY2025 · Results reported
EPS $1.04 · Revenue $0.00
View filing
Sep 30, 2025
IPO
Sep 29, 2025
FY2024 · Annual results
EPS $-86.24 · Revenue $0.00
View filing
Mar 31, 2025
Q3 FY2024 · Results reported
EPS $0.09 · Revenue $0.00

Financial Statements of LNAI

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-178.0M	-101.3%	-42.9%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-7.9M	+28.7%	+4.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	-47.7%	-1760.7%	+32.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	0.04x	-45.5%	+652.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$8.2M	-95.0%	+47.9%

Actual vs Estimate

A —Q —

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	—	—	—	—
Revenue Surprise	—	—	—	—

Leadership Team of LNAI

2 executives

Name	Title	Compensation	Gender	Year Born	Status
David H. Weinstein	Chief Executive Officer & Director	USD 421,894	Male	1961	Active
Nathen Fuentes	Chief Financial Officer	USD 279,684	Male	1983	Active

Recent News of LNAI

PRNewsWire8/27/2026Neutral

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5 WILMINGTON, Del. and SACRAMENTO, Calif.

PRNewsWire8/4/2026Neutral

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and pharmaceutical partnering. SACRAMENTO, Calif.

PRNewsWire8/4/2026Neutral

Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

Amended Complaint Alleges 29.6 Million Failed to Deliver Shares and Single Day Trading Volume of 15.3 Times Shares Outstanding, Company Seeks Treble Damages Under Federal RICO Statute WILMINGTON, Del. and SACRAMENTO, Calif.

PRNewsWire6/17/2026Neutral

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ -- Fellow Shareholders, Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building a next-generation biotechnology company at the intersection of artificial intelligence, and national security and biology.

Benzinga6/17/2026Neutral

Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session

Lunai Bioworks Inc. shares soared 80.88% after-hours after regaining Nasdaq compliance with minimum bid price requirements.

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Lunai Bioworks Inc.

Contact Information

Recent history

Q3 FY2025 · Results reported

Q2 FY2025 · Results reported

Q1 FY2025 · Results reported

IPO

FY2024 · Annual results

Q3 FY2024 · Results reported

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session

Related stocksBiotechnology

Recent history

Q3 FY2025 · Results reported

Q2 FY2025 · Results reported

Q1 FY2025 · Results reported

IPO

FY2024 · Annual results

Q3 FY2024 · Results reported

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session